Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...

—This recent analysis found that, despite similar clinical outcomes, genomic differences were observed in mCRPC differences by race, highlighting the importance of racial diversity in future genomic ...

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

Metformin effects on renal function in mCRPC during PSMA radiopharmaceutical therapy (RPT): A retrospective analysis. Clinical and demographic disparities in prostate cancer patients undergoing ...

Ceramides-lipid molecules in cells that affect many physiological functions including cell differentiation, migration, and death-and their metabolites have been implicated in the development of cancer ...

A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer ...

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alter ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and quality of life for patients. The FDA has approved darolutamide (Nubeqa; Bayer ...

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer.  | After winning a broader FDA label in metastatic castration-resistant prostate cancer, ...

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study Participants had ...

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...